Skip to main content
NCBI home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1981 Dec;56(12):934–938. doi: 10.1136/adc.56.12.934

Spironolactone therapy in infants with congestive heart failure secondary to congenital heart disease.

S M Hobbins, R S Fowler, R D Rowe, A G Korey
PMCID: PMC1627485  PMID: 7036914

Abstract

The efficacy of treatment with spironolactone for congestive heart failure secondary to congenital heart disease was studied in 21 infants under 1 year of age. All received digoxin and chlorothiazide. In addition, group A (n = 10) was given supplements of potassium and group B (n = 11) received spironolactone. Daily clinical observations of vital signs, weight, hepatomegaly, and vomiting were recorded. Paired t test analysis showed significant reduction in liver size and weight (P less than 0.01) and respiratory rate (P less than 0.05) in group B, and less significant decreases in group A. The incidence of vomiting was slightly lower in group B. We conclude that the addition of spironolactone hastens and enhances the response to standard treatment with digoxin and chlorothiazide in infants with congestive heart failure.

Full text

PDF
934

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. CARRUTHERS B. M., LEDRAY R. D., SERAGLIA M., MCINTOSH H. W., WALSH G. C. EFFECT OF AN ALDOSTERONE ANTAGONIST (SPIRONOLACTONE) ON PATIENTS WITH SEVERE CONGESTIVE HEART FAILURE. Can Med Assoc J. 1963 Sep 28;89:633–641. [PMC free article] [PubMed] [Google Scholar]
  2. COX J. R., DAVIES-JONES A. B., LEONARD P. J. SODIUM CONTENT AND URINARY ALDOSTERONE EXCRETION IN PATIENTS WITH CONGESTIVE HEART FAILURE BEFORE AND AFTER TREATMENT AND COMPARISON WITH NORMAL SUBJECTS UNDERGOING SALT RESTRICTION. Clin Sci. 1964 Feb;26:177–184. [PubMed] [Google Scholar]
  3. Cohen S. N., Doyle E. F., Rutkowski M. M. Drug therapy of heart disease in pediatric patients. I. Congestive heart failure in infancy and concepts of developmental pharmacology. Am Heart J. 1973 Jul;86(1):133–137. [PubMed] [Google Scholar]
  4. Hickie J. B., Lazarus L. Aldosterone metabolism in cardiac failure. Australas Ann Med. 1966 Nov;15(4):289–300. doi: 10.1111/imj.1966.15.4.289. [DOI] [PubMed] [Google Scholar]
  5. KAGAWA C. M., STURTEVANT F. M., VAN ARMAN C. G. Pharmacology of a new steroid that blocks salt activity of aldosterone and desoxycorticosterone. J Pharmacol Exp Ther. 1959 Jun;126(2):123–130. [PubMed] [Google Scholar]
  6. LARAGH J. H. Hormones and the pathogenesis of congestive heart failure: vasopressin, aldosterone, and angiotensin II. Further evidence for renal-adrenal interaction from studies in hypertension and in cirrhosis. Circulation. 1962 Jun;25:1015–1023. doi: 10.1161/01.cir.25.6.1015. [DOI] [PubMed] [Google Scholar]
  7. LENZI F., CANIGGIA A., DI PERRI T., GUIDERI R., RAVENNI G. Aldosterone in congestive heart failure. Acta Med Scand. 1959 Mar 23;163(4):329–339. [PubMed] [Google Scholar]
  8. LIDDLE G. W. Aldosterone antagonists. AMA Arch Intern Med. 1958 Dec;102(6):998–1004. doi: 10.1001/archinte.1958.00260230144018. [DOI] [PubMed] [Google Scholar]
  9. Nicholls M. G., Espiner E. A., Donald R. A., Hughes H. Aldosterone and its regulation during diuresis in patients with gross congestive heart failure. Clin Sci Mol Med. 1974 Oct;47(4):301–315. doi: 10.1042/cs0470301. [DOI] [PubMed] [Google Scholar]
  10. Rance C. P., Arbus G. S., Balfe J. W., Kooh S. W. Persistent systemic hypertension in infants and children. Pediatr Clin North Am. 1974 Nov;21(4):801–824. doi: 10.1016/s0031-3955(16)33062-0. [DOI] [PubMed] [Google Scholar]
  11. VANDER A. J., WILDE W. S., MALVIN R. L. Stop flow analysis of aldosterone and steroidal antagonist SC-8109 on renal tubular sodium transport kinetics. Proc Soc Exp Biol Med. 1960 Mar;103:525–527. doi: 10.3181/00379727-103-25581. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES